207 related articles for article (PubMed ID: 32295565)
21. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
Dichtel LE; Carpenter LL; Nyer M; Mischoulon D; Kimball A; Deckersbach T; Dougherty DD; Schoenfeld DA; Fisher L; Cusin C; Dording C; Trinh NH; Pedrelli P; Yeung A; Farabaugh A; Papakostas GI; Chang T; Shapero BG; Chen J; Cassano P; Hahn EM; Rao EM; Brady RO; Singh RJ; Tyrka AR; Price LH; Fava M; Miller KK
Am J Psychiatry; 2020 Oct; 177(10):965-973. PubMed ID: 32660299
[TBL] [Abstract][Full Text] [Related]
22. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
23. Minocycline augmentation in older adults with persistent depression: an open label proof of concept study.
Avari JN; Kanellopoulos D; Solomonov N; Oberlin L; Alexopoulos GS
Int Psychogeriatr; 2020 Jul; 32(7):881-884. PubMed ID: 32690123
[TBL] [Abstract][Full Text] [Related]
24. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
Umbricht D; Niggli M; Sanwald-Ducray P; Deptula D; Moore R; Grünbauer W; Boak L; Fontoura P
J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32663909
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.
Fekadu A; Mesfin M; Medhin G; Alem A; Teferra S; Gebre-Eyesus T; Seboxa T; Assefa A; Hussein J; Lemma MT; Borba C; Henderson DC; Hanlon C; Shibre T
Trials; 2013 Nov; 14():406. PubMed ID: 24279305
[TBL] [Abstract][Full Text] [Related]
26. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
Nettis MA; Lombardo G; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Sforzini L; Bogdanova A; Cleare A; Young AH; Pariante CM; Mondelli V
Neuropsychopharmacology; 2021 Apr; 46(5):939-948. PubMed ID: 33504955
[TBL] [Abstract][Full Text] [Related]
27. Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol.
Eisendrath SJ; Gillung EP; Delucchi KL; Chartier M; Mathalon DH; Sullivan JC; Segal ZV; Feldman MD
BMC Complement Altern Med; 2014 Mar; 14():95. PubMed ID: 24612825
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
29. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
30. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
[TBL] [Abstract][Full Text] [Related]
31. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.
Soczynska JK; Kennedy SH; Alsuwaidan M; Mansur RB; Li M; McAndrews MP; Brietzke E; Woldeyohannes HO; Taylor VH; McIntyre RS
Bipolar Disord; 2017 May; 19(3):198-213. PubMed ID: 28599348
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
33. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
34. Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.
Hasebe K; Mohebbi M; Gray L; Walker AJ; Bortolasci CC; Turner A; Berk M; Walder K; Maes M; Kanchanatawan B; Ashton MM; Berk L; Ng CH; Malhi GS; Singh AB; Dean OM
Acta Neuropsychiatr; 2022 Aug; 34(4):220-227. PubMed ID: 34937590
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
37. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.
Dean OM; Maes M; Ashton M; Berk L; Kanchanatawan B; Sughondhabirom A; Tangwongchai S; Ng C; Dowling N; Malhi GS; Berk M
Clin Psychopharmacol Neurosci; 2014 Dec; 12(3):180-8. PubMed ID: 25598820
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
[TBL] [Abstract][Full Text] [Related]
39. PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.
Au-Yeung SK; Griffiths J; Roberts S; Edwards C; Yu LM; Bogacz R; Rendell J; Attenburrow MJ; Watson S; Chan F; Cipriani A; Cleare A; Harmer CJ; Kessler D; Evans J; Lewis G; Singh I; Simon J; Harrison PJ; Cowen P; Shanyinde M; Geddes J; Browning M
Evid Based Ment Health; 2022 May; 25(2):77-83. PubMed ID: 34810175
[TBL] [Abstract][Full Text] [Related]
40. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
